NCT07217496 2026-03-17
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
University of California, San Francisco
Phase 1 Withdrawn
Clinical Trials
11 trialsNCT05574504 2024-08-01
Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy
AdventHealth
Phase 2 Withdrawn
NCT05894447 2024-04-12
Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers
Weill Medical College of Cornell University
Phase 1 Withdrawn
NCT06018116 2024-02-15
CANUCK-01
CHU de Quebec-Universite Laval
Phase 2 Withdrawn
NCT06050954 2023-11-09
CARMA
Fox Chase Cancer Center
Phase 2 Withdrawn
NCT04179110 2022-02-22
Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor
Yale University
Phase 2 Withdrawn
NCT03238664 2018-01-02
Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for Thermal Ablation of Muscle Invasive Cells in Patients With Bladder Tumors
University of Southern California
Phase NA Withdrawn
NCT01071928 2015-08-19
Second-Line Docetaxel + ASA404 for Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT01907308 2014-04-29
Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma
University of Colorado, Denver
Phase 2 Withdrawn
NCT00696007 2012-02-17
Neoadjuvant Chemotherapy Plus Nephroureterectomy for Locally Advanced Upper Tract Transitional Cell Cancer
Lahey Clinic
Phase 2 Withdrawn
NCT00172367 2008-09-26
Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma
National Taiwan University Hospital
Phase 2 Withdrawn